Scientific Program Day 2 | Thursday, February 23, 2023
7:25 am Registration & Coffee
8:25 am Chairperson’s Opening Remarks
Widening the Therapeutic Index Through Next-Generation Payloads, Conjugation Technologies & Formats
8:30 am Development of TPD² – Combining the Power of Protein Degradation With the Precision of Antibodies for Next-Generation ADCs
Synopsis
- Examining the potency of GSPT1 degrader as a payload
- Discussing improved pharmacokinetic properties
- Outlining improved safety and tolerability
9:00 am Extracellular Targeted Protein Degradation: An Emerging Therapeutic Modality
Synopsis
• Advancements in Targeted Protein Degradation research shows that targeted removal can now be accomplished external to the classic ligase-ubiquitination pathway found within cells
• Novel bispecific antibodies, antibody-conjugates, and bifunctional small molecules can all drive engagement and clearance of extracellular plasma and membrane protein targets
• Describing the application of these bifunctional conjugate tools in rapidly removing the cardiovascular disease-relevant protein PCSK9 in mice
9:30 am Technology-Enabled Payload Solutions to Broaden the Scope of Conjugatable Drugs
Synopsis
- Discover how P5-labelling enables rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
- Review how novel technology broadens the scope of drugs that are available for conjugation
- Evaluate this superior linker-payload platform for the efficient and steady delivery of different APIs
10:00 am Looking to Satisfy the Growing Demand of Capacity & Capabilities for ADCs
Synopsis
- Discusssing ADC landscape trends and analysis
- Evaluating whether to outsource or do in-house
- Providing a quick overview and updated on BSPs services and solutions
10:15 am Morning Break & Networking
10:45 am PEG based bispecific antibody drug conjugates
Synopsis
- Outlining the challenges of ADC development to treat solid tumors
- Discussing PEG based bispecific ADCs to overcome these challenges
11:15 am Beyond ADCs – Next Generation Targeted Therapeutics
Synopsis
High-capacity conjugates have advanced in parallel with that of ADCs, and now the two can be put together as next generation targeted high-capacity drug conjugates
Advantages of Targeted High-capacity Drug Conjugates (T-HDCs) include:
- T-HDC has ~10x DAR for both targeted and bystander-mediated cell-killing
- High DAR allows use of moderate potent payloads and can avoid highly toxic agents (e.g. auristatins)
- Payload delivery is optimized for PK and biodistribution with broad therapeutic index
- Payload is protected from circulatory components
- Targeting allows flexibility of binder (mAb, FAB, Peptide,…)
- Targeting can leverage multi-valency for binding targets or multi-specificity for multiple targeting
Development advantages for T-HDCs include the ease of ‘mix and match’ for multiple product constructs with optimized high-capacity drug conjugates and different targeting binders
11:45 am Addressing the Limitations of ADCs with Targeted C’Dot Drug Conjugates (CDCs)
Synopsis
- Discover how CDCs are capable of selective tumor targeting across a range of antigen expression and deep tumor penetration not possible with ADCs
- Examine how CDCs are capable of crossing disrupted Blood Brain Barrier to localize in and treat primary and metastatic brain tumors
- Learn about ELU001, a CDC with 22 exatecan payloads and 13 folic acid targeting moieties that is currently being evaluated in early phase clinical trials
12:15 pm Lunch
Showcasing Novel & Out of the Box Technologies
1:15 pm Bispecific XDC – A Versatile Drug Delivery Platform
Synopsis
- Outlining the design and mechanism of Bi-XDC: Leveraging bi-ligand synergies on multiple dimensions to drug the undruggable targets
- Reviewing the pipeline of Bi-XDC Platform: Transforming bioactive molecule to drugs, including toxins, protein degraders, immune-regulators, radionuclides, macromolecules, cells
1:45 pm AMDC – Antibody Mimetic Drug Conjugates: Precision Engineered Medicines
Synopsis
- Discussing Cupid-Pysche: A novel and proprietary platform delivering a variety of payloads to multiple tumor associated antigen targets
- Analyzing a system for the rapid in vivo validation of antibody mimetic targeting ligands and the evaluation of therapeutic payloads including chemotherapeutics, immunotherapies, alpha emitting radioisotopes, and a proprietary photoimmunotherapy
2:15 pm Creating Next-Generation Immunotherapeutics Using Novel Chemistry Platform Technologies
Synopsis
- Bright Peak Therapeutics is developing a portfolio of next-generation precision immunotherapies powered by novel chemistry technologies
- Introducing Bright Peak’s platform technologies for preparing next-generation immunocytokines. Chemical protein synthesis platform yields enhanced optimized cytokines as payloads that are then conjugated to ‘off-the-shelf’ antibodies using a unique chemical conjugation platform to access nextgeneration immunocytokines
- Discussing preclinical data of select immunocytokines prepared using Bright Peak’s platform for application in immunooncology
2:45 pm Afternoon Break & Refreshments
Examining Radioconjugates as Next-Generation Conjugates
3:15 pm Advancing the Development of a Pipeline of Differentiated Radiotherapeutics for Cancer
Synopsis
• Actinium is a leading speciality oncolcoy radiotherapeutics company with a paradigm shifting induction and conditioning agent, Iomab-B, with positive topline results for R/R AML
• Actimab-A investigated in multiple R/R AML trials including in combination with Bcl-2 targeted venetoclax and the salvage chemotherapy CLAG-M with latter showing meaningful improvement in response rates and overall survival
• Strong R&D platform of targeted radiotherapies in preclinical development for heme and solid tumor malignancies bolstered by multiple collaborative research partnerships with Astellas, AVEO/LG Chem and EpicentRX
3:45 pm The New Emerging Pillar in Oncology
Synopsis
• Outlining radiopharmaceuticals as a new frontier in oncology
• Discussing how radiopharmaceuticals work
• Sharing a unique MoA in RAD pipeline
4:15 pm Antibody Radionuclide Conjugates (ARC) for Therapeutic Applications on Cancer Expressing CA19-9
Synopsis
• Chelator bundles are built upon multi-arm linkers; each bundle carries 3 chelator molecules
• Two chelator bundles are conjugated site-specifically to an antibody molecule; an ARC molecule bears 6 chelator molecules
• An ARC with anti-CA19-9 and 177Lu-labeled DOTA is to be illustrated
4:45 pm Targeted Copper Theranostics (TCTs) – Next Generation Payloads for Targeted Molecular Imaging & Therapy of Cancer
Synopsis
• Development of novel Targeted Copper Theranostics (TCTs) for molecular imaging and radionuclide therapy using copper-67
• Pre-clinical and clinical data demonstrating safety and efficacy of TCTs
• Outlining future opportunities for functionalizing ADCs as TCTs – 3Rs: Rescue, Repurpose, Repositioning